Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ERG | P11308 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22265594 | 0.88 | HSD11B1 (0.52) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL22265591 | 0.88 | HSD11B1 (0.52) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL22265345 | 0.87 | HSD11B1 (0.43) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL22265348 | 0.87 | HSD11B1 (0.43) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL29523162 | 0.87 | SMO (0.42) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL22265347 | 0.87 | HSD11B1 (0.43) | SMODGAT1HSD11B1MAPTLMNA | |
| SCHEMBL22280443 | 0.86 | HDAC6 (0.49) | HSD11B1HPGDSHDAC6HDAC8MAPT | |
| SCHEMBL29522926 | 0.85 | HDAC6 (0.43) | SMODGAT1HSD11B1HPGDSHDAC6 | |
| SCHEMBL22280307 | 0.85 | MAPK1 (0.50) | HPGDSHDAC6HDAC8MAPTLMNA | |
| SCHEMBL22280491 | 0.84 | SMO (0.47) | SMODGAT1HSD11B1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | SMO 504/4885DGAT1 3758/4885HSD11B1 1833/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | SMO 2184/4885DGAT1 3063/4885HSD11B1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.